Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

Table 1 Patient characteristics

	Total cohort	3-year completers
Number of patients	84	31
Female sex, n (%)	60 (71%)	21 (68%)
APOE ε4 carrier, n (%)	57 (69%)	21 (68%)
Age at onset, years^a	73.9 ± 7.1	73.3 ± 8.8
Age at start of treatment, years^a	76.7 ± 7.0	76.9 ± 8.2
Illness duration, years^a	3.0 ± 1.8	3.6 ± 2.3
Education, years^a	10.1 ± 2.9	9.9 ± 2.9
MMSE score at baseline^a	22.7 ± 4.0	23.2 ± 3.8
ADAS-cog score (0 to 70) at baseline^a	17.1 ± 8.2	15.2 ± 8.3
IADL score at baseline^a	13.4 ± 5.0	14.0 ± 6.0
MMSE score after 3 years^a (n = 31)		21.7 ± 4.6
ADAS-cog score after 3 years^a (n = 29)		20.7 ± 13.2
IADL score after 3 years^a (n = 24)		22.6 ± 5.8

^aMean ± standard deviation. ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination.

ISSN: 1758-9193